Document Type
Article
Publication Date
10-1-2013
Publication Title
Endocrine
ISSN
1355-008X
Volume
44
Issue/No.
2
First Page
525
Last Page
31
Abstract
The discovery of a novel non-AT1, non-AT2 binding site for angiotensins in the rodent brain and testis that is unmasked by the organomercurial compound para-chloromercuribenzoic acid (PCMB) has catalyzed efforts to purify and characterize this protein. We recently reported that this protein is neurolysin and now report upon the specificity of this binding site for various neuropeptides. Competition binding assays in rat brain and testis used (125)I-Sar(1), Ile(8) angiotensin II (Ang II) as the radioligand in the presence of saturating concentrations of AT1 and AT2 receptor antagonists and 100 μM parachloromercuribenzoate. Primary screening of 36 peptides and other compounds at 10 μM concentration revealed seven peptides that inhibited specific binding >50 %: ghrelin, Tyr(1) S36057 (a melanin-concentrating hormone receptor ligand), orphanin FQ and its congeners (Tyr(1) and Tyr(14)), Dynorphin A (1-8), and Ang (1-9). The selective neurolysin inhibitor Proline-Isoleucine dipeptide was inactive at 1 mM. These results suggest that the ability of PCMB to unmask high affinity binding of Ang II to neurolysin is a pharmacological effect and that neurolysin may significantly affect the activity of the renin-angiotensin system.
NSUWorks Citation
Swindle, Jamala D.; Santos, Kira L.; and Speth, Robert C., "Pharmacological characterization of a novel non-AT1, non-AT2 angiotensin binding site identified as neurolysin" (2013). HPD Articles. 76.
https://nsuworks.nova.edu/hpd_facarticles/76
ORCID ID
0000-0002-6434-2161
DOI
10.1007/s12020-013-9898-x
Copyright
Copyright © 2013, Springer Science Business Media New York
